New Perspectives in the Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease: Novel Uses of Biomarkers by Subirana-Mirete, Judit
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
New Perspectives in the Diagnosis of Mild Cognitive
Impairment and Alzheimer’s Disease: Novel Uses of
Biomarkers
Judit Subirana-Mirete
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64322
Abstract
Criteria  for  the  diagnosis  of  Alzheimer’s  disease  were  established  in  1984  by  the
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)
and the Alzheimer’s Disease and Related Disorders Association (ADRDA). Common‐
ly used since their implementation, these criteria are becoming obsolete for everyday
practice,  and a review is  being claimed.  Three groups of  experts  consisting of  re‐
nowned experts  from the  National  Institute  on Aging (NIA)  and the  Alzheimer’s
Association proposed a set of recommendations to modify the criteria in this field of
research. Two notable differences from the initial criteria were included: the incorpo‐
ration of biomarkers and the formalization of different disease stages in the diagnos‐
tic criteria. From now on, mild cognitive impairment is incorporated in the diagnosis
as another stage of dementia. However, the new criteria are still under revision and are
currently of use for research purposes with the aim to get the definitive modification
for  the  clinical  criteria.  This  chapter  presents  the  main  developments  in  research
concerning Alzheimer’s disease and mild cognitive impairment to define these new
research criteria.
Keywords: Alzheimer’s disease, mild cognitive impairment, biomarkers, neuropsy‐
chology, dementia
1. Introduction
The concept of dementia makes us instantly think about a set of characteristic symptoms and
the resulting repercussions for patients and their families. The objective of this chapter is to
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update our ideas about Alzheimer’s disease and get to know the beginning and evolution of the
construct of mild cognitive impairment, as well as the new advances in genetics and biomark‐
ers that, in not such a distant future, will be of common use in the diagnosis of cognitive
impairment.
The Greeks were the first to study mental disorders from a scientific point of view by separating
the study of mind from religion. The existence of dementia has been known since the times of
Hippocrates (460–370 BC), although throughout history, it has been given different names:
paranoia, idiocy, senility, senile psychosis, and so on. But it will not be until 1906 that Alois
Alzheimer first described the disease that would be named after him and which has made
history worldwide [1].
From Dr. Alois Alzheimer’s first patient, Auguste D., until the current description and
definition of the disease, more than a century has passed and many research studies have been
carried out on it. Initially, it was considered to be a condition particular to young patients, and
so it was given the name of presenile dementia. However, the progressive increase in life
expectancy left uncovered that the symptoms present in Auguste D. were also found in older
population, thus leading to a new approach to the disease. But it was not until the 1970s that
the disease described by Alzheimer started to be a focus of attention. The real story of the
concept of dementia and Alzheimer’s disease can be consulted in different texts of reference
[1–3].
Recently, knowledge on dementia in general and on Alzheimer’s disease in particular has been
remarkably expanded. The diagnostic process for Alzheimer’s disease has benefitted from
widely accepted consensus protocols [4]. Nevertheless, the clinical heterogeneity of this
disease (age of onset, type of impairment, or the disease’s progression pace) makes diagno‐
sis extremely difficult.
2. Diagnosis of Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative condition of insidious onset and progressive
evolution, characterized by loss of memory and other cognitive functions, and by a set of
noncognitive symptoms, among which depressive or psychotic-related symptoms and
behaviour disorders stand out. Among the main neuropsychological features of this disease,
we can point at the progressive impairment of memory and language, the decline in visuo‐
spatial and motor capacities, and the disruption of executive functions such as the capacity for
abstraction and reasoning [5, 6].
The criteria for the clinical diagnosis of Alzheimer’s disease were defined in 1984 by the
National Institute of Neurological and Communicative Disorders (NINCD) and the Alzheim‐
er’s Disease and Related-Disorders Association (ADRDA). These criteria are based on the idea
that Alzheimer’s disease is a single clinicopathological entity [7], thus advocating that
Alzheimer’s disease always has a close correlation between clinical symptoms and their
pathological basis; in most cases, it was thought that the typical anatomopathological presen‐
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tation already described in 1910 and based on the presence of senile plaques, neurofibrillary
tangles and cerebral arteriosclerotic changes [8] would be found at autopsy. Following this
idea, the basic lines for the development of the disease were, in 1984, as follows:
1. The underlying pathology of Alzheimer’s disease and clinical symptoms was developed
concurrently.
2. Patients either had completely developed Alzheimer’s disease symptoms (in this case,
then, they clearly had a dementia), or they were free of this pathology and, therefore, had
no dementia at all (at least no Alzheimer-like dementia as later identified).
Thus, 1984 criteria required the presence of cognitive impairment and dementia to be
confirmed by neuropsychological assessment in order to establish the diagnosis of possible or
probable Alzheimer’s disease, although histopathological confirmation was still needed for a
final diagnosis (via autopsy or biopsy) (see Table 1).
 NINCDS-ADRDA (1984) criteria for the clinical diagnosis of Alzheimer’s disease
  Diagnostic criteria for probable Alzheimer’s disease:
 Presence of dementia:
 - Established by clinical examination
 - Documented by the Mini-Mental Cognitive Examination
 Test, Blessed Dementia Scale or similar
 - Confirmed by neuropsychological tests
 - Deficits in two or more areas of cognition
 - Progressive worsening of memory and other cognitive functions
 - No disturbance of consciousness
 - Onset between ages 40 and 90
 - Absence of systemic disorders or other brain disease
 that could cause dementia
  Diagnostic criteria for possible Alzheimer’s
 disease:
 - Dementia syndrome in the absence of other
 causes and in the presence of variations in the
 onset, in the presentation, or in the clinical
 course
 - Presence of another systemic or brain
 disorder sufficient to produce dementia,
 which is not considered to be the cause of the
 dementia
 - Presence of a single, progressive severe
 cognitive deficit
  Criteria that support the diagnosis of probable Alzheimer’s
 disease:
 - Progressive deterioration of specific cognitive functions (e.g.,
 language, motor skills, perception
 - Impaired activities of daily living (ADL) and altered patterns of
 behaviour
 - Family history of similar disorders
 - Consistency in analytic results (lumbar puncture, EEG, CT)
 Diagnostic criteria for definite Alzheimer’s
 disease:
 - Meeting the clinical criteria for probable
 Alzheimer’s disease with histopathologic
 evidence
  Features nonconsistent with the diagnosis of Alzheimer’s disease:
 - Sudden onset
 - Focal neurologic signs
 - Seizures or early gait disturbances
Source: Adapted from Carrasco [21].
Table 1. Criteria for the diagnosis of Alzheimer’s disease.
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Some aspects of these criteria have been set aside by new research and daily clinical practice
has also pointed at ideas to be revised. The pathological histology present in Alzheimer’s
disease can also be found in a wide set of alternative clinical conditions [9, 10], from patients
without cognitive symptoms to patients with mild cognitive impairment (MCI) or other types
of impairment. Therefore, the initial concept of Alzheimer’s disease has to be less restrictive
than that developed in 1984.
The capacity to recognize some clinical symptoms in other disorders with a similar develop‐
ment as in Alzheimer’s disease was limited two decades ago, thus resulting in diagnostic
confusions. In this respect, for example, reversible systemic disorders such as vitamin B12
deficiency, which may have similar symptoms to a dementia, were not taken into consideration
[11]. Although frontotemporal dementia was considered to be an entity, others such as Lewy
body dementia or vascular dementia were not taken into account [12]. Likewise, the concept
of aphasia linked to neurodegenerative disorders, despite being described some years before
the NINCDS-ADRDA criteria [13], was not fully developed until two decades later [14].
The implication that memory impairment must always be considered as the primary cognitive
deficit for the diagnosis of Alzheimer’s disease is also being put into doubt, as clinical experi‐
ence has showed that Alzheimer’s disease may be developed in a nonamnesic way [15]. Clinical
experience has also pointed at the need to revise cut-off points by age for the diagnosis, as age-
related pathologies such as dementia are more and more frequent due to the overageing of
population. Finally, the inclusion of new results from neuroimaging exploration and biomark‐
er clinical analysis in the new criteria will allow us to get to know the individual characteristics
of every cognitive impairment from an integral approach of the same construct.
Since the establishment of the NINCDS-ADRDA criteria 32 years ago, it has been proved that
Alzheimer’s disease underlying pathology and clinical symptoms are not always present
concurrently, thus dismissing one of the main assumptions of the 1984 diagnostic criteria.
Research has evolved remarkably since then and, among other events, it has been identified,
for example, that in the absence of any apparent symptom, there can be a wide pathological
presentation (particularly of amyloid plaques) [16, 17].
Knowledge about the neuropathology of Alzheimer’s disease has been expanded in the last
25 years of the twentieth century; new sets of diagnostic criteria to establish a diagnosis of this
disease from its neuropathological basis have been developed and applied more or less
successfully. Among others, we have to consider those by the National Institute on Aging
(NIA) [18], those by the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)
[19], and those by the NIA-Reagan Institute [20]. There are no basic differences among these
three classifications; they all stand out the need to carry out an inclusive diagnosis, establish
the priority for the cognitive diagnosis—with special emphasis on memory—and consider
other noncognitive or psychiatric symptoms to be “accessory” [21]. These approaches present
two main problems: first, they downplay cognitive symptoms, as they only focus on amnesic
manifestations, with the other cognitive functions and psychopathological impairments being
left in the background; second, they are limited by the inability to categorize certain symptoms
present in this kind of dementia [22]. Nevertheless, there are two main research aspects that
have evolved from the very first description of this disease: using biomarkers and formally
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establishing different stages for the disease. Literature on mild cognitive impairment has
exponentially increased since the 1990s in order to document the gradual impairment of
cognitive functions preceding the point when there is a significant interference with activities
of daily living [23]. As previously mentioned, the 1984 criteria did not consider cognitive
impairment that does not reach the dementia threshold, thus passing over that the Alzheimer’s
disease underlying pathology slowly develops for years—or even decades—before there is a
clinical manifestation of the disease.
3. Mild cognitive impairment
Different nosological entities have been defined in order to characterize cognitive impairment
processes that represent an intermediate stage between cognitive decline observed in the
ageing process and changes that meet the criteria for the diagnosis of dementia [24]. The most
used concept is that of “mild cognitive impairment” (MCI) coined by Petersen et al. [25],
although initially described by Flicker et al. [26] according to Reisberg’s Global Deterioration
Scale [27].
MCI is a syndrome that shows up as a cognitive dysfunction greater than expected for the
patient’s age and cultural and educational level, that develops without major interferences in
activities of daily living and does not meet criteria for dementia [25, 28]. The main diagnostic
difference between Alzheimer’s disease and mild cognitive impairment lies in the degree of
interference in the patient’s capacity to develop daily work or regular tasks. This is, unavoid‐
ably, a determination to be carried out by an expert on the basis of individual circumstances
and the description of daily routines obtained by both the patient and a close informant. For
a further development of this differential diagnosis, please see Albert et al. [29].
The definition in Petersen [21] describes MCI as a degenerative process that precedes dementia
—on the basis of the cognitive continuum construct (Figure 1), where the main deficit concerns
memory and the other cognitive functions seem to be stable. Later studies have expanded the
MCI construct by describing different subtypes not only limited to amnestic symptoms [30].
Nelson and O’Connor [31] described, through postmortem histopathological studies with MCI
patients, that a wide majority of cases evolved to a process of dementia, although a small
percentage did not. These results put into question the assumption that MCI may always be
considered as an initial stage of Alzheimer’s disease.
As we get closer to the definition of the earliest stages of cognitive impairment, the dissociation
between the connotations of the concept of early Alzheimer’s disease and MCI is more obvious.
It is becoming clearer and clearer that both Alzheimer’s disease pathophysiological process
and symptoms are better explained as a continuum (linking both Alzheimer’s disease and MCI
at the same time), as these processes can concurrently evolve and even overlap in time [32].
Hence the need to revise both constructs further.
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Figure 1. Model of cognitive continuum. Adapted from Sperling et al. [32].
Although some agreement has been reached in the last few years, the current MCI diagnosis
is complex as there are no precise and standardized criteria with general consensus. As main
characteristics, we can stand out the complaints about memory loss from the beginning of the
process, reported either by an informant or by the patients themselves. Patients often report
other symptoms, such as difficulties to find needed words, loss of personal objects, disorien‐
tation, or loss of continuity in usual tasks, for example, in a conversation [31].
There have been attempts to formalize these clinical observations as diagnostic criteria. We
can stand out those by the Study Group on Dementia and Behavioral Disorders of the Spanish
Society of Neurology [33] or those by Mayo Clinic [25] that correspond to the amnestic subtype
only. Also worth highlighting are those by the International Psychogeriatric Association (IPA)
[34], described in Table 2.
Despite the efforts to agree on diagnostic criteria for MCI, there are still some difficulties
deriving, in many cases, from conceptual limitations of the nosological entity itself [24]. Since
the Montreal Consensus [35], criteria became more flexible, with the inclusion, for instance,
not only of patients in a cognitive normality dementia transition stage but also very prevalent
intermediate conditions secondary to other aetiologies (e.g., vascular dementia) or other
conditions, also very frequent, such as those secondary to mood disorders [36].
One of the facts that has always been an object of attention is the relationship between MCI
and dementia, in particular, Alzheimer’s disease [30, 37]. A recently published study [38]
reports the prevalence for mild cognitive impairment between 3 and 42% depending on the
construct. We should remember now that, before Petersen et al.’s definition of MCI [25], other
constructs had been considered such as age-associated memory impairment (AAMI) [27] or
cognitive impairment no dementia (CIND) [39]. In particular, according to Ward’s study,
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AAMI prevalence is between 3.6 and 38.4%; the prevalence for CIND ranges between a bit
more than 5 and 35.9%, whereas studies using the concept of MCI (as described by Petersen)
show population prevalence between 3 and 42%. Moreover, if we consider that MCI patients
have a three times higher risk to develop Alzheimer’s disease in a period of 4.5 years after
diagnosis [40], the need for some criteria that are agreed upon, global and useful for the
diagnosis of cognitive impairment in all of its stages, from onset to more serious stages,
becomes particularly important.
Diagnostic criteria according to the International Psychogeriatric Association (IPA) and World Health Organization
(WHO)
1. No age restriction
2. Decline of cognitive function reported by patient or informant
3. Decline is gradual and present for at least 6 months
4. Deterioration in any major cognitive domain:
- Memory and learning
- Attention and concentration
- Language
- Thinking
- Visuospatial functioning
5. Lower scores in mental state evaluations or neuropsychological tests, a standard deviation below the mean value
of a control group
6. No presence of brain processes, either systemic or psychiatric, that can account for the impairment
Source: Adapted from Sánchez-Rodríguez and Torrellas-Morales [28].
Table 2. IPA criteria.
Since 2009 there has been a consensus among the main research centres, that diagnostic criteria
for Alzheimer’s disease, as well as those for dementia and mild cognitive impairment, should
be revised. For this reason, the National Institute on Aging (NIA), together with the Alzheim‐
er’s Association, sponsored a deep revision of criteria, thus establishing a revision of old criteria
by three independent groups of experts. The first group undertook to establish and describe
diagnostic criteria for dementia and Alzheimer’s disease; the second group focused on the
symptomatic stage prior to Alzheimer-like dementia; finally, the third group dealt with the
asymptomatic stage prior to dementia and mild cognitive impairment. The recommendations
of the three groups were presented at the 2010 International Conference on Alzheimer’s
Disease and later published [41]. This new proposal of criteria has integrated research on
dementia, MCI, and Alzheimer’s disease carried out in the last 25 years of the twentieth
century. In particular, the inclusion of genetic breakthroughs, biomarkers, and final formali‐
zation of the different stages in the development of dementia are worth standing out.
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4. New advances in research
The role of genetics in the diagnosis of the different types of cognitive impairment is more and
more active and important. At present, there is no doubt about the existence of genetic risk
factors to develop Alzheimer’s disease, as some genes have been identified that are not only
responsible for the genetically pure forms of the disease but also some sporadic and late-onset
forms [42].
Although the most important risk factor related to Alzheimer’s disease is the ageing process
of the patient, the second risk factor is the family history of the disease. Thus, Alzheimer’s
disease is a complex pathology with a clear genetic component. Up to now, three genes have
been found to be responsible for early onset familial Alzheimer’s disease: the gene for amyloid
beta precursor protein (APP), the gene for presenilin-1 (PS1), and the gene for presenilin-2
(PS2). Taking this into account, if the predominant autosomal form of Alzheimer’s disease is
present in a patient with MCI, then this MCI is more likely to be a prodrome of early onset
Alzheimer’s disease [43].
But not only is early onset Alzheimer’s disease linked to genetic influence. Approximately,
40% of diagnosed individuals have a family history of the disease, and epidemiological studies
show that the risk of developing the disease if a first-degree relative already has it is between
two and three times higher than that of general population [44]. The genetic component of late-
onset Alzheimer’s disease has been targeted in many studies, but at the moment only a genetic
component, APOE, has been considered as a risk factor associated with the disease [43]. Thus,
up to now, the presence of one or two ε4 alleles in the gene for apolipoprotein E (APOE) has
been the only genetic variation widely accepted as a risk factor to develop late-onset Alzheim‐
er’s disease, whereas the presence of the ε2 allele would have the opposite effect [45]. Evidence
suggests, then, that an individual meeting clinical, cognitive, and etiological criteria for MCI
and carrier of the ε4 allele of the APOE gene is more likely to progress towards developing
Alzheimer’s disease, eventually, than any other individual without this genetic characteristic.
Genetic research has also allowed us to know that the molecular mechanisms that start
Alzheimer’s disease, both clinically and pathologically, correspond to a metabolic disorder of
amyloid beta (Aβ) [46]. A key point is the concept according to which some usually soluble
neuronal proteins can misfold and aggregate, for instance, in neurofibrillary tangles, thus
producing high levels of cell cytotoxicity [47]. Recent data suggest that although familial
Alzheimer’s disease is characterized by Aβ overproduction, sporadic late-onset forms are
characterized by a decrease in Aβ recycling capacity. And Aβ traffic is controlled by APOE,
so the genetic data available at the moment overwhelmingly point at the amyloid cascade
hypothesis as the starter of the cognitive impairment process [48].
To facilitate the theoretical discussion of the MCI construct as a preclinical stage of Alzheimer’s
disease, the group revising the criteria [32] proposed a theoretical model to explain the
relationship between cognitive decline and the basic pathophysiology of Alzheimer’s disease
(see Figure 2). As will be seen later, genetic factors are not the only determinants in the
development and progression of mild cognitive impairment, as other risk factors, such as
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vascular factors or the history of personal development, as well as environmental factors and
cognitive reserve, which can positively influence the development of cognitive symptoms of
decline, also have to be considered.
Figure 2. Relationship between cognitive decline and the basic pathophysiology of Alzheimer’s disease. Based on
Sperling et al. [32].
Another remarkable difference between the 1984 criteria and those revised in 2011 is the
incorporation of biomarkers to diagnose cognitive impairment. Biomarkers are physiological,
biochemical, or anatomic parameters that are measured in vivo and that reflect specific
characteristics of pathophysiological processes related to a disease; in this case, MCI or
Alzheimer’s disease. It is important to incorporate new knowledge on biomarkers into the
diagnostic framework of these diseases, as, on the one hand, they provide us with greater
support when establishing the etiological bases of the cognitive decline process and thus allow
us to better choose the intervention to follow when there are effective specific treatments; on
the other hand, they allow us to determine the probability of the cognitive and functional
progression of impairment towards a more serious stage of MCI or towards dementia, as well
as the possibility that this progression develops in a defined period of time [29].
There are many biomarkers. Nevertheless, after a long and thorough study of the main
markers, the study groups selected only two categories of biomarkers to be included in their
recommendations. These are the biomarkers related to Aβ and the biomarkers reflecting
neuronal injury [29].
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The amyloid plaques (or senile plaques) are one of the most characteristic features of Alz‐
heimer’s disease and, therefore, those biomarkers that can detect and quantify Aβ protein or
tau protein accumulated in brain tissue are vitally important for the pathological diagnosis of
the disease and its precursors [49]. Aβ deposition markers include both measurements of the
level of Aβ42 in cerebrospinal fluid (CSF) as evidence of deposition via positron emission
tomography (PET) imaging by using a variety of specific binding agents [50]. Tau protein
accumulation markers can be obtained through measurements via CSF.
Among neuronal injury markers, there is a series of structural and functional measures,
described in Table 3, together with Aβ biomarkers.
Biomarkers for the diagnosis of cognitive impairment
Biomarkers of Aβ deposition
- CSF Aβ42
- PET amyloid imaging
Biomarkers of neuronal injury
- CSF tau/phosphorylated-tau
- Hippocampal volume or medial temporal atrophy by volumetric measures
- Rate of brain atrophy
- FDG-PET imaging
- SPECT perfusion measures
Other non-validated measures: fMRI activation studies, resting BOLD functional connectivity, MRI perfusion, MR
spectroscopy, and diffusion tensor imaging.
Abbreviations: CSF, cerebrospinal fluid; PET, positron emission tomography; FDG, fluorodeoxyglucose; SPECT, single
photon emission tomography; fMRI, functional magnetic resonance imaging; BOLD, blood oxygen level-dependent;
MR, magnetic resonance.
Adapted from Albert et al. [29].
Table 3. Biomarkers for clinical diagnosis.
Among the potential uses of biomarkers, there is the identification of people in the preclinical
stages of the disease or the reduction in the heterogeneity of the disease in clinical trials.
However, not all biomarkers are valid as indirect assessment criteria, as they can be difficult
to validate and require different levels of validation depending on their expected use. In this
respect, although the presence of high levels of tau protein is clearly associated with the
pathophysiological process of Alzheimer’s disease, changes in tau and phosphorylated-tau (p-
Tau) are not exclusive to Alzheimer’s disease and can also reflect more general neuronal and
synaptic damage. The same can be said of Aβ depositions, as they are not exclusive to
Alzheimer’s disease. This is one of the main limitations of these biomarkers [51]. No conclusive
determination has been reached either concerning whether the quantitative measure of these
biomarkers provides us with more information than the dichotomous assessment (presence/
absence; positive/negative). Nevertheless, the combination of both types of measures points
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at the higher probability that the pathophysiological process of the disease is the etiological
base of underlying changes [29].
One of the main drawbacks in Alzheimer’s disease research is that the symptoms of the disease
appear after significant neuronal loss. The objective of current research with biomarkers is to
manage to prevent this loss before the final emergence of symptoms, in order to develop really
efficient treatments against this disease, as current medication can only provide patients with
short-term improvements of their cognitive function [52].
5. New criteria for research on mild cognitive impairment and
Alzheimer’s disease
After thoroughly analysing the background and revising the main research studies carried out
at the epidemiological, neuropsychological, genetic levels, and with biomarkers, the group of
experts of the National Institute on Aging and the Alzheimer’s Association proposed a
working framework (Figure 3) to provide specialists, and the scientific world in general, with
a specific and common language to move towards the knowledge of the preclinical and clinical
stages of Alzheimer’s disease.
The objective of the group of experts is to contribute with some operational research criteria
in order to help select future target groups at risk of developing Alzheimer’s disease, by
considering the presence of Aβ biomarkers (either in isolation or in combination with other
neurodegeneration markers). We have to consider that, at the moment, the use of these new
criteria is for research only and that an inappropriate use in other fields may lead to wrong
results and misinterpretations, as so far these criteria are still under revision.
These new criteria are based on the assumption that Alzheimer’s disease is characterized by a
sequence of biological events that begin much before the clinical symptoms of the disease
appear. Considering the genetic evidence, the hypothesis of Aβ accumulation in a first stage
of amyloidosis, which would be the first moment when cognitive impairment can be measured,
is gaining strength. This first stage occurs before any other symptomatic manifestation and,
therefore, would allow for a first diagnosis, which would indicate that a still indefinable
process has started. At the same time, the new criteria acknowledge that the preclinical stages
of Alzheimer’s disease represent a continuum, including those cases that will never go beyond
stage 1 or 2. The presence of one or two biomarkers, once the MCI stage has been reached,
would indicate that an individual is experiencing a neurodegenerative process that in further
stages will be defined.
As the group of experts highlights in their conclusions [32], at the moment, these criteria are
to be used only in research and have no diagnostic utility; the objective of the new criteria is
to allow researchers to better characterize the biological sequence that triggers Alzheimer’s
disease from the first moments. Therefore, these criteria have to facilitate the standardization
of data collection in new studies, whose results will modify the very same criteria.
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Figure 3. New proposal for research criteria for MCI and Alzheimer’s disease.
6. Neuropsychological contributions to the early detection of cognitive
impairment
Research has highlighted, beyond the genetic base, a series of factors that have a crucial
significance in the development and course of cognitive impairment and Alzheimer’s disease.
There is great interest in knowing, for example, the association between two facts: cognitive
impairment and metabolic and vascular alterations, such as cardiovascular diseases, high
blood pressure, diabetes, or obesity, on the one hand, and the establishment and course of the
disease, on the other. Understanding these relationships and obtaining data via clinical studies
can help us understand that the fact of reducing risk factors associated to these pathologies
may be also useful to control Alzheimer’s disease. Moreover, a healthy balanced diet, physical
Molecular Mechanisms of the Aging Process and Rejuvenation108
exercise, social commitment, and mentally challenging activities can help people to keep
healthy as they get older [53].
With regard to environmental factors, included in the diagram of Figure 2, different studies
show that a higher educational level, complex working activities or a socially integrated
lifestyle are factors that can help to postpone the onset of clinical cognitive impairment [54,
55]. It has also been shown that physical exercise and cardiovascular activity have long-term
benefits on cognition [56]. Actually, physical activity has been proved to reduce the risk of
developing dementia and to improve cognition [57].
On the other hand, vascular risk factors are associated, by definition, to vascular dementia. In
contrast, the relationship between vascular risk factors and the development and progression
of cognitive impairment associated with Alzheimer’s disease is less clear. For more than three
decades, Alzheimer’s disease has been described as a primary neurodegenerative disorder
with scarce, or none, vascular foundation [5, 58]. Nevertheless, in the last few years, knowledge
about this relationship has increased a lot and many current studies relate vascular risk factors
to the pathogenesis of mild cognitive impairment and Alzheimer’s disease (see De la Torre for
a thorough theoretical revision [59]).
Knowledge about the risk factors of Alzheimer’s disease has expanded a lot, and at present,
they include not only risk factors particular to the ageing and adulthood process but also risk
factors particular to all life stages. For example, perinatal conditions, brain development,
growth factors, socioeconomic conditions, or cognitive reserve are factors that have been
shown to have an influence on the process of developing dementia [60, 61].
The identification of prodromal neuropsychological markers in cognitive impairment is based
on the idea that neuronal loss starts much earlier than clinical symptoms. For this, it is essential
to clinically detect individuals in the first stages of impairment, as starting treatment in these
early moments would help to maximize the impact on maintaining cognitive functions and
functional skills. Hence, the importance of having adapted tests to detect cognitive impairment
at early stages, as an early diagnosis of cognitive impairment at prodromal stages is still a very
important objective, considering the probability that this stage will be susceptible to treatments
designed both to stop and to slow down the progression of the impairment.
In summary, literature suggests that the risk of starting a process of cognitive impairment
linked to Alzheimer’s disease is not determined only by a genetic component or by certain risk
factors in adulthood, but by the result of a complex interaction between genetic and environ‐
mental factors throughout our entire life.
In the next decades, an increase in the prevalence of Alzheimer’s disease in particular and
cognitive impairment in general is expected. Advances in clinical research will make the
management of this disease more sophisticated. In the near future, there will be new tests to
identify both people at risk of developing Alzheimer’s disease and those having early symp‐
toms of cognitive impairment. At the same time, there will be more medicines available and
possibly the progression of the disease may be delayed for years. With the improvement in
diagnosis and early detection of Alzheimer’s disease, more people will be diagnosed at the
early stages of the disease. The role of the family will be more and more crucial, as together
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with early diagnosis and pharmacological treatment there will be coordination of care and
support functions both for patients and for carers of people with dementia. Many of these
individuals will have the added value of still being there for their families, to look after
children, for example, or being an important part in the ageing of the parents themselves. To
improve care and support to these people, the public and private sectors have to work together
to eliminate age-related barriers that reduce access to help and support services and to improve
the comprehension of the unique needs of the people diagnosed with Alzheimer’s disease and
their environment.
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